Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2021-05-04 Capital/Financing Update
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a statement addressed to stock exchanges regarding the deviation or variation in utilization of funds raised by Morepen Laboratories Limited. It references Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of deviations in fund utilization. The document states there is no deviation or variation for the quarter ended March 31, 2021. It includes details about the mode of fund raising (preferential issue of warrants), amount raised, and utilization status. The document is a regulatory compliance disclosure about fund utilization and does not contain financial statements or detailed financial results. It is not a full financial report, earnings release, or management discussion. The document is short (3844 characters) and serves as a formal notification to the stock exchanges about fund utilization status. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on fundraising and capital usage.
2021-05-04 English
Financial Result Updates
Audit Report / Information Classification · 95% confidence The document contains a detailed auditor's report from Satinder Goyal & Co. Chartered Accountants on the audited standalone and consolidated financial results of Morepen Laboratories Limited for the quarter and financial year ended March 31, 2021. It includes the auditor's opinion, basis for opinion, management's responsibility, and auditor's responsibilities, which are typical components of an audit report. The document also references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to financial results disclosures. The presence of detailed financial data and the auditor's report indicates this is not merely an announcement but the actual audit report. Therefore, the document fits the category of an Audit Report / Information (AR).
2021-05-04 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q4’FY21) May, 2021' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter and full fiscal year ended March 31, 2021, including revenue, profit, segment-wise growth, and equity updates. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The content includes forward-looking statements, business strategy, and detailed financial highlights typical of an investor presentation. There is no indication that this is a full annual report (10-K) or interim report (IR), nor is it a regulatory filing or certification. The presence of detailed financial and operational data aimed at investors confirms it is an Investor Presentation.
2021-05-04 English
Investors Presentation (Q4'FY21) May, 2021
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q4’FY21) May, 2021' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter and full fiscal year ended March 31, 2021, including revenue, profit, segment-wise growth, and equity updates. The content is structured as a presentation with charts and forward-looking statements, typical of investor presentations. There is no indication that this is a full annual report, audit report, or earnings release summary. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2021-05-04 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 4, 2021, announcing Morepen Laboratories Limited's financial performance for the fiscal year ended March 31, 2021. It highlights key financial metrics such as net profit, revenue growth, EBITDA, and segment performance. The document includes detailed financial figures and business updates but is presented as a press release rather than a formal earnings report or annual report. It does not contain comprehensive financial statements or detailed management discussion and analysis typical of an Annual Report (10-K) or Interim Report (IR). The document is longer than 5,000 characters and contains substantive financial data, but its format and content align with an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights. Therefore, the appropriate classification is Earnings Release (ER). FY 2021
2021-05-04 English
Press Release - 'Morepen records stellar 189% jump in Net Profits and 39% growth in the Revenue in FY21 - Company to setup world class R&D Centre at Baddi (HP)'
Capital/Financing Update Classification · 85% confidence The document is a press release dated May 4, 2021, announcing Morepen Laboratories Limited's financial performance for the fiscal year ended March 31, 2021. It highlights key financial metrics such as net profit, revenue growth, EBITDA, and segment performance. The document includes consolidated quarterly and annual financial figures and discusses business developments like the setup of a new R&D center and expansion plans. The text is a public announcement of financial results rather than a detailed financial report or filing. It does not contain comprehensive financial statements or management discussion and analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) exactly, as it is a press release with detailed financial highlights but not a formal earnings announcement document. Given the nature and content, the best fitting category is Capital/Financing Update (CAP) because it includes financial performance highlights and mentions capital raising activities (allotment of shares on preferential basis). However, since it is primarily a press release on financial results and company updates, and not a formal earnings release or annual report, CAP is the closest match. Confidence is high due to clear financial performance data and capital structure updates in the text.
2021-05-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.